目的:这项在堪萨斯城的堪萨斯城VA医疗中心进行的质量改进研究,密苏里州,调查了SysmexDI-60集成载玻片处理系统在整合到日常实践中时改善血液学周转时间的能力。它进一步解决了与周转时间变化相关的潜在患者护理因素。
方法:在2022年5月至2023年2月之间检查了三个月的手册和SysmexDI-60患者数据。白细胞(WBC)范围,周转时间,工作时间,和研究月份使用双尾未配对t检验和百分比变化进行分析。使用双尾进一步分析了这些类别中的标本数量,2样本比例测试。
结果:这项质量改进研究表明,SysmexDI-60系统在总体上以及各种WBC和工作班次的周转时间上都显着减少。对于WBC浓度小于2.0×103/µL且浓度在参考范围内,周转时间的统计学上最显著的改善发生。此外,轮班的周转时间有了显著的改善。
结论:SysmexDI-60系统大大减少了差速器的周转时间,因此,通过提供及时的结果可能使患者护理受益。减少周转时间可能会加快急诊科的入院和出院,并加强对肿瘤科患者的护理。它还可以通过Sysmex分析仪为具有假阳性标志的患者提供更及时的结果,这也可能有助于临床医生的决策。
OBJECTIVE: This quality improvement study conducted at the Kansas City VA Medical Center in Kansas City, Missouri, investigated the Sysmex DI-60 Integrated Slide Processing System\'s ability to improve hematology turnaround times when integrated into daily practices. It further addressed potential patient care factors associated with changes in turnaround times.
METHODS: Three months of manual and Sysmex DI-60 patient data were examined between May 2022 and February 2023. White blood cell (WBC) ranges, turnaround times, working hours, and study months were analyzed using 2-tailed unpaired t testing and percentage change. The number of specimens in these categories was further analyzed using 2-tailed, 2-sample proportion testing.
RESULTS: This quality improvement study indicated that the Sysmex DI-60 system produced a statisitcally significant reduction in turnaround times overall and for various ranges of WBCs plus work shifts. The most statistically significant improvement in turnaround times occurred for WBC concentrations less than 2.0 × 103/µL and concentrations within the reference range. In addition, the off shifts experienced a notable improvement in turnaround times.
CONCLUSIONS: The Sysmex DI-60 system substantially decreases turnaround times for differentials, thus potentially benefiting patient care by providing prompt results. It is possible that reducing turnaround times could expedite emergency department admissions and discharges as well as enhance care for the oncology department\'s patients. It could also lead to more timely results for patients with false-positive flags by the Sysmex analyzer, which may also help with clinician decision-making.